Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants

Cancer Epidemiology Biomarkers and Prevention

Volumn 10, Issue 6, 2001, Pages 657-661

  Carbone, Paul P ^a,b   Pirsch, John D ^b   Thomas, James P ^a   Douglas, Jeffrey A ^a,b   Verma, Ajit K ^a,b   Larson, Paul O ^a,b   Snow, Stephen ^a,b   Tutsch, Kendra D ^a   Pauk, Diane ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; POLYAMINE; PREDNISONE;

ADULT; AMELANOTIC MELANOMA; ARTICLE; BIOASSAY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; ORGAN TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; SKIN CANCER; TOXICITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; EFLORNITHINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; ORNITHINE DECARBOXYLASE; PLACEBOS; SKIN NEOPLASMS;

EID: 0034905908     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Incidence of skin cancer in 5356 patients following organ transplantation
2. Skin cancer in transplant recipients
3. Incidence and treatment of neoplasia after transplantation
4. Neoplastic complications of transplantation
5. Cancer development in cadaveric donor renal allograft recipients treated with azothiopurine (AZA), cyclosporine (CyA), or AZA/CyA
6. Correlation of the inhibition by retinoids of tumor promoter-induced mouse epidermal ornithine decarboxylase activity and of skin tumor promotion
7. Clinical development plan: α-difluoromethylornithine (DFMO)
8. Toxicity evaluation of difluoromethylornithine: Doses for chemoprevention trials
9. The validity and practicality of sun-reactive skin types I through VI
10. Chemical peeling and aging skin
11. Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy
12. In vitro induction of human skin ornithine decarboxylase by the tumor promoter 12-0-tetradecanoylphorbol-13-acetate
13. A precolumn derivatization high-performance liquid chromatographic (HPLC) procedure for the quantification of difluoromethylornithine in plasma
14. Solid-phase extraction and determination of dansyl derivatives of unconjugated and acetylated polyamines by reversed-phase liquid chromatography: Improved separation systems for polyamines in cerebral spinal fluid, urine, and tissue
15. Skin cancer in liver transplant recipients
16. Skin cancer in Australian heart transplant recipients
17. Skin cancers in organ transplant recipients
18. Retinoids in prevention of skin cancer
19. 13-cis-Retinoic acid and cancer chemoprevention
20. The state-of-the-art in chemoprevention of skin cancer
21. Inhibition of tumor promotion by DL-α-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase
22. Inhibition of phorbol ester-induced human epidermal ornithine decarboxylase activity by oral compounds: A possible role in human chemoprevention studies
23. Randomized Phase I chemoprevention dose-seeking study of α-difluoromethylornithine
24. Phase I protocol chemoprevention study of piroxicam and α-difluoromethylornithine
25. Kinetics of α-difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylase
26. 1-acetyltransferase: The turning point in polyamine metabolism